91 related articles for article (PubMed ID: 21810690)
1. Is there a role for bortezomib combinations in the management of patients with follicular lymphoma?
Salles G
J Clin Oncol; 2011 Sep; 29(25):3349-50. PubMed ID: 21810690
[No Abstract] [Full Text] [Related]
2. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study.
Fowler N; Kahl BS; Lee P; Matous JV; Cashen AF; Jacobs SA; Letzer J; Amin B; Williams ME; Smith S; Saleh A; Rosen P; Shi H; Parasuraman S; Cheson BD
J Clin Oncol; 2011 Sep; 29(25):3389-95. PubMed ID: 21810687
[TBL] [Abstract][Full Text] [Related]
3. Management of relapsed/refractory follicular lymphoma.
Martin P
Clin Adv Hematol Oncol; 2018 Apr; 16 Suppl 10(4):1-12. PubMed ID: 29851937
[No Abstract] [Full Text] [Related]
4. Efficacy and toxicity of two schedules of bortezomib in patients with recurrent or refractory follicular lymphoma: a randomised phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA).
Ribrag V; Tilly H; Casasnovas O; Bosly A; Bouabdallah R; Delarue R; Boue F; Bron D; Feugier P; Haioun C; Offner F; Coiffier B
Eur J Cancer; 2013 Mar; 49(4):904-10. PubMed ID: 23273434
[TBL] [Abstract][Full Text] [Related]
5. Management of Relapsed and Refractory Hodgkin Lymphoma in 2018.
Rutherford SC; Leonard JP
JAMA Oncol; 2018 Aug; 4(8):1120-1121. PubMed ID: 30003234
[No Abstract] [Full Text] [Related]
6. Rethinking Prognosis and Therapy for Follicular Lymphoma.
Jacobson CA; Freedman AS
J Clin Oncol; 2015 Aug; 33(23):2489-91. PubMed ID: 26169620
[No Abstract] [Full Text] [Related]
7. Management of relapsed or refractory follicular lymphoma patients in daily practice - a French non-interventional study.
Feugier P; Brice P; Maynadié M; Franchi-Rezgui P; Hacini M; Laurent G; Suc E; Fitoussi O; Solal-Celigny P; Damaj G; Haioun C; Leconte P; Lazreg F; Boissard F; Pau D; Salles G
Leuk Lymphoma; 2018 Oct; 59(10):2485-2488. PubMed ID: 29486625
[No Abstract] [Full Text] [Related]
8. Histone deacetylase inhibitors in multiple myeloma.
Pratt G
Lancet Oncol; 2013 Oct; 14(11):1038-1039. PubMed ID: 24055413
[No Abstract] [Full Text] [Related]
9. New hope for relapsed and refractory multiple myeloma.
Leleu X
Lancet Oncol; 2013 Oct; 14(11):1028-1029. PubMed ID: 24007745
[No Abstract] [Full Text] [Related]
10. Management of patients with relapsed/refractory metastatic colorectal cancer.
Grothey A
Clin Adv Hematol Oncol; 2019 Mar; 17 Suppl 7(3):14-16. PubMed ID: 31730591
[No Abstract] [Full Text] [Related]
11. Timing (and biology) are everything.
Fine HA
Neuro Oncol; 2014 Nov; 16(11):1431-2. PubMed ID: 25314963
[No Abstract] [Full Text] [Related]
12. Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
Mey UJ; Orlopp KS; Flieger D; Strehl JW; Ho AD; Hensel M; Bopp C; Gorschlüter M; Wilhelm M; Birkmann J; Kaiser U; Neubauer A; Florschütz A; Rabe C; Hahn C; Glasmacher AG; Schmidt-Wolf IG
Cancer Invest; 2006 Oct; 24(6):593-600. PubMed ID: 16982464
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab and lenalidomide induced remission in refractory double-hit lymphoma.
Chan TS; Khong PL; Kwong YL
Ann Hematol; 2016 Oct; 95(11):1917-8. PubMed ID: 27473194
[No Abstract] [Full Text] [Related]
14. Role of endosonography in rectal lymphoma.
Gavioli M; Bagni A; Garoia C; Piccagli I; Biscardi A; Natalini G
Haematologica; 2000 Aug; 85(8):882-3. PubMed ID: 10942946
[No Abstract] [Full Text] [Related]
15. Paraneoplastic peripheral blood eosinophilia in relapsed follicular lymphoma.
Okosun J; McNamara C
Leuk Lymphoma; 2011 Feb; 52(2):328-30. PubMed ID: 21133729
[No Abstract] [Full Text] [Related]
16. Paraneoplastic pemphigus occurring after bendamustine and rituximab therapy for relapsed follicular lymphoma.
Higo T; Miyagaki T; Nakamura F; Shinohara A; Asano H; Abe H; Senda N; Yoshizaki A; Fukayama M; Kurokawa M
Ann Hematol; 2015 Apr; 94(4):683-5. PubMed ID: 25199505
[No Abstract] [Full Text] [Related]
17. Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma.
Craig M; Hanna WT; Cabanillas F; Chen CS; Esseltine DL; Neuwirth R; O'Connor OA
Br J Haematol; 2014 Sep; 166(6):920-8. PubMed ID: 25039282
[TBL] [Abstract][Full Text] [Related]
18. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.
Dimopoulos M; Siegel DS; Lonial S; Qi J; Hajek R; Facon T; Rosinol L; Williams C; Blacklock H; Goldschmidt H; Hungria V; Spencer A; Palumbo A; Graef T; Eid JE; Houp J; Sun L; Vuocolo S; Anderson KC
Lancet Oncol; 2013 Oct; 14(11):1129-1140. PubMed ID: 24055414
[TBL] [Abstract][Full Text] [Related]
19. Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients.
Sacchi S; Pozzi S; Marcheselli L; Bari A; Luminari S; Angrilli F; Merli F; Vallisa D; Baldini L; Brugiatelli M;
Cancer; 2007 May; 109(10):2077-82. PubMed ID: 17394190
[TBL] [Abstract][Full Text] [Related]
20. Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia.
Elter T; James R; Busch R; Winkler D; Ritgen M; Böttcher S; Kahl C; Gassmann W; Stauch M; Hasan I; Staib P; Fischer K; Fink AM; Bahlo J; Bühler A; Döhner H; Wendtner CM; Stilgenbauer S; Engert A; Hallek M
Leukemia; 2012 Dec; 26(12):2549-52. PubMed ID: 22584787
[No Abstract] [Full Text] [Related]
[Next] [New Search]
